Back to top

blockchain: Archive

Zacks Equity Research

Can Vivint Smart Home (VVNT) Climb 33% to Reach the Level Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 33.4% in Vivint Smart Home (VVNT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Can Bandwidth (BAND) Climb 90% to Reach the Level Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 90.3% in Bandwidth (BAND). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

BANDNegative Net Change

Zacks Equity Research

Can TTM (TTMI) Climb 31% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for TTM (TTMI) points to a 30.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

TTMINegative Net Change

Zacks Equity Research

How Much Upside is Left in Intra-Cellular (ITCI)? Wall Street Analysts Think 33%

The consensus price target hints at a 33.5% upside potential for Intra-Cellular (ITCI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

How Much Upside is Left in UDR (UDR)? Wall Street Analysts Think 44%

The consensus price target hints at a 43.7% upside potential for UDR (UDR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

UDRPositive Net Change

Zacks Equity Research

Wall Street Analysts Predict a 73% Upside in Kiniksa Pharmaceuticals, Ltd. (KNSA): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 72.7% in Kiniksa Pharmaceuticals, Ltd. (KNSA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

KNSAPositive Net Change

Zacks Equity Research

HSBC (HSBC) Just Overtook the 20-Day Moving Average

Should investors be excited or worried when a stock crosses above the 20-day simple moving average?

HSBCNegative Net Change

Zacks Equity Research

Danaos (DAC) Just Reclaimed the 20-Day Moving Average

When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?

DACPositive Net Change

Zacks Equity Research

SPX Technologies, Inc. (SPXC) Hit a 52 Week High, Can the Run Continue?

SPX Technologies (SPXC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

SPXCNegative Net Change HSCPositive Net Change

Zacks Equity Research

Belden Inc (BDC) Hit a 52 Week High, Can the Run Continue?

Belden (BDC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

BDCNegative Net Change